KYBoo
2021-12-14
Good
Hyphens Pharma inks exclusive licensing deal with Favorex to commercialise biosimilar in Singapore, Malaysia, Philippines
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":607922235,"tweetId":"607922235","gmtCreate":1639477536840,"gmtModify":1639477536947,"author":{"id":3581501341719005,"authorId":3581501341719005,"authorIdStr":"3581501341719005","name":"KYBoo","avatar":"https://static.tigerbbs.com/43072e3bdf1be8a6c0fb9e0d7c8a0558","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good</p></body></html>","htmlText":"<html><head></head><body><p>Good</p></body></html>","text":"Good","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/607922235","repostId":1170691908,"repostType":4,"repost":{"id":"1170691908","pubTimestamp":1639474809,"share":"https://www.laohu8.com/m/news/1170691908?lang=&edition=full","pubTime":"2021-12-14 17:40","market":"sg","language":"en","title":"Hyphens Pharma inks exclusive licensing deal with Favorex to commercialise biosimilar in Singapore, Malaysia, Philippines","url":"https://stock-news.laohu8.com/highlight/detail?id=1170691908","media":"businesstimes","summary":"CATALIST-LISTED Hyphens Pharma has inked an exclusive licensing deal to commercialize an antibody bi","content":"<div>\n<p>CATALIST-LISTED Hyphens Pharma has inked an exclusive licensing deal to commercialize an antibody biosimilar drug in Singapore, Malaysia, and the Philippines, in order to expand their dermatology ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/companies-markets/hyphens-pharma-inks-exclusive-licensing-deal-with-favorex-to-commercialise\">Web Link</a>\n\n</div>\n","source":"lsy1607307803821","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hyphens Pharma inks exclusive licensing deal with Favorex to commercialise biosimilar in Singapore, Malaysia, Philippines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHyphens Pharma inks exclusive licensing deal with Favorex to commercialise biosimilar in Singapore, Malaysia, Philippines\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-14 17:40 GMT+8 <a href=https://www.businesstimes.com.sg/companies-markets/hyphens-pharma-inks-exclusive-licensing-deal-with-favorex-to-commercialise><strong>businesstimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CATALIST-LISTED Hyphens Pharma has inked an exclusive licensing deal to commercialize an antibody biosimilar drug in Singapore, Malaysia, and the Philippines, in order to expand their dermatology ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/companies-markets/hyphens-pharma-inks-exclusive-licensing-deal-with-favorex-to-commercialise\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"1J5.SI":"凯帆药剂国际有限公司"},"source_url":"https://www.businesstimes.com.sg/companies-markets/hyphens-pharma-inks-exclusive-licensing-deal-with-favorex-to-commercialise","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170691908","content_text":"CATALIST-LISTED Hyphens Pharma has inked an exclusive licensing deal to commercialize an antibody biosimilar drug in Singapore, Malaysia, and the Philippines, in order to expand their dermatology product offerings for Asia.\nThe pharmaceutical and consumer healthcare company announced on Tuesday (Dec 14) that it has signed an exclusive license and supply agreement with Favorex, a subsidiary of DKSH, to commercialize Ustekinumab biosimilar, produced by multinational biopharmaceutical company Alvotech.\nBiosimilars are close copies of biological drugs with expired or expiring patents. The Ustekinumab biosimilar, which is undergoing clinical studies, is a human monoclonal antibody that aims to treat immune-mediated disorders such as plaque psoriasis, psoriatic arthritis and Crohn's disease. Worldwide sales of Ustekinumab are estimated to reach US$8.4 billion in 2021, according to an online report.\nLim See Wah, executive chairman and chief executive officer of Hyphens Pharma, said in a press statement: \"Dermatology is one of our focus areas and we want to bring to market innovative medical dermatological products to meet the needs of patients suffering from various skin disorders.\"\n\"We were interested to add Ustekinumab to our product portfolio because of its dermatology indications, which we believe will help to enhance our dermatology product offerings for Asia,\" he added.\nThe exclusive license and supply agreement will not have a material effect on the net tangible assets or earnings per share of Hyphens Pharma International - of which Hyphens Pharma is a subsidiary - for the financial year ending Dec 31, said Hyphens Pharma.\nAt 5 pm, shares of Hyphens Pharma were trading at S$0.30, up S$0.005 or 1.7 percent.","news_type":1},"isVote":1,"tweetType":1,"viewCount":161,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/607922235"}
精彩评论